Phaseline

Targets › SGLT2

SGLT2 (Sodium/glucose cotransporter 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Sep 2027.

Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. (UniProt, P31639)

Open in Phaseline: the race on SGLT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
EMSBERLIM 25/20 ASSOCIATION
SGLT2 inhibitor (empagliflozin 25 mg) combined with HMG-CoA reductase inhibitor (rosuvasta
SGLT2, LDLRPhase 3Dyslipidemia Associated With Type II Diabetes MellitusSep 2027

Conditions

Dyslipidemia Associated With Type II Diabetes Mellitus (1)

Modalities

small molecule (1)

Companies

EMS (1)

Related targets

LDLR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.